TY  - JOUR
T1  - Carcinosarcoma of the uterus: Possible sequelae of long-term tamoxifen therapy for breast cancer
A1  - Mohammad Azam
A1  - Rahat Hadi
A1  - Ashish Singhal
A1  - Sambit Nanda
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2015
VL  - 4
IS  - 6
DO  - 10.4103/2278-0513.169115
SP  - 717
EP  - 719
N2  - Carcinosarcoma (CS) of the uterus is rare and accounts for 1–2% of all uterine malignancies, occur commonly in postmenopausal women. These are highly aggressive tumors with poor prognosis and often present at advanced stage. Tamoxifen (TAM) has been known to increase the incidence of endometrial carcinoma from 1 to 2 cases per 1000 women/year and of uterine sarcoma from 0.04 to 0.17 cases per 1000 women/year. TAM has weakly estrogenic properties that can produce endometrial cell proliferation and, consequently, TAM use increases the risk of endometrial cancer by approximately two- to three-fold. Currently, no consensus is present regarding the management of Uterine CS. However, surgery plays an important role in the management along with chemotherapy (CT) and radiotherapy as an adjuvant. We report a case of a woman who developed malignant mixed mullerian tumor of uterus after taking TAM for 6 years as adjuvant hormonal therapy for breast carcinoma.
UR  - https://ccij-online.org/article/carcinosarcoma-of-the-uterus:-possible-sequelae-of-long-term-tamoxifen-therapy-for-breast-cancer-490
ER  -